Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations

BACKGROUND AND OBJECTIVES: Protease inhibitors such as darunavir are an important therapeutic option in the anti-human immunodeficiency virus arsenal. Current dosage guidelines recommend using cobicistat- or ritonavir-boosted darunavir 800 mg every 24 h (q24h) in protease inhibitor-naïve patients, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Stillemans, Gabriel, Belkhir, Leila, Vandercam, Bernard, Vincent, Anne, Haufroid, Vincent, Elens, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862523/
https://www.ncbi.nlm.nih.gov/pubmed/32696441
http://dx.doi.org/10.1007/s40262-020-00920-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862523/
https://www.ncbi.nlm.nih.gov/pubmed/32696441
http://dx.doi.org/10.1007/s40262-020-00920-z

Ejemplares similares